Skip to main content
Windlas Biotech Limited logo

Windlas Biotech Limited — Investor Relations & Filings

Ticker · WINDLAS ISIN · INE0H5O01029 LEI · 3358008HGGLMCSC4GP83 BSE.NS Manufacturing
Open in API
Filings indexed 432 across all filing types
Latest filing 2026-02-05 Earnings Release
Country IN India
Listing BSE.NS WINDLAS

About Windlas Biotech Limited

https://www.windlasbiotech.com

Windlas Biotech Limited is a Contract Development and Manufacturing Organization (CDMO) providing integrated services from formulation development to commercial-scale production. The company specializes in manufacturing solid and liquid oral dosage forms, including tablets, capsules, sachets, and liquid orals. Its operations encompass three primary business verticals: CDMO services for domestic and multinational firms, trade generics, and over-the-counter (OTC) brands. Windlas maintains advanced research and development facilities focused on process optimization and complex generic formulations. The product portfolio covers diverse therapeutic areas such as gastrointestinal, cardiovascular, anti-diabetic, and respiratory health. The company emphasizes scalable manufacturing solutions and adherence to global quality standards to support the product lifecycles of its pharmaceutical partners.

Recent filings

Filing Released Lang Actions
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated February 5, 2026, from Windlas Biotech Limited reporting its unaudited financial results for the nine months and third quarter of fiscal year 2026 (9M & Q3FY26). It contains detailed financial highlights such as revenue, EBITDA, PAT, EPS, and segment performance for the specified periods. The document is titled as a press release and is addressed to stock exchanges for record purposes. It is not a full annual or interim report but an initial announcement of quarterly/periodical financial results with key highlights. The length of the document (9873 characters) and the content confirm it is a financial results announcement rather than a full report or regulatory filing. Therefore, the appropriate classification is Earnings Release (ER).
2026-02-05 English
Investor Presentation
Investor Presentation Classification · 95% confidence The document is a detailed presentation titled 'Windlas Biotech Limited Investor Presentation – 9M & Q3FY26' dated February 5, 2026. It includes comprehensive financial highlights, management commentary, business verticals, revenue breakdowns, and consolidated financial performance for the nine months and third quarter of fiscal year 2026. The content is typical of an investor presentation focusing on financials, strategy, and market position rather than a formal quarterly report or earnings release. The document is lengthy (15,000 characters) and contains substantive financial data and analysis, consistent with an investor presentation rather than a brief earnings release or regulatory filing. Therefore, the appropriate classification is Investor Presentation (IP).
2026-02-05 English
Outcome of Board Meeting
Regulatory Filings
2026-02-05 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 90% confidence The document is a letter from Windlas Biotech Limited addressed to stock exchanges announcing the schedule of a conference call to discuss the financial performance for the quarter and nine months ended December 31, 2025. It includes details about the date, time, and dial-in information for the earnings call. There is no actual financial data or detailed report included, only an announcement of the upcoming call. This fits the definition of a Call Transcript (CT) only if it contained the full transcript, but here it is just a notice of the call. It is not an Annual Report, Interim Report, or Earnings Release since it does not contain financial results or highlights, only the schedule and invitation. Therefore, the best classification is Call Transcript (CT) as it relates to the earnings call event, even though it is a pre-call announcement, it is closest to CT rather than other categories. Confidence is high because the document explicitly states it is a schedule for a conference call to discuss financial performance.
2026-01-29 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-01-28 English
Board Meeting — Financial Results
Regulatory Filings Classification · 95% confidence The document is a notice of a Board Meeting scheduled to consider and approve the un-audited financial results for a quarter and nine months period. It is a short announcement informing stock exchanges about the upcoming meeting and related trading window closure. It does not contain any financial data or results itself, nor is it a full report. The document is under 5,000 characters and serves as a notification rather than the actual financial report. Therefore, it fits the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2026-01-28 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.